MiRNA (micro Ribonucleic Acid) combined marker and application thereof in preparation of cancer detection and / or prognosis prediction product

Through the detection of miRNA combination markers miR-125b-5p, miR-411-5p and miR-99a-5p, head and neck squamous cell carcinoma detection and prognosis models were constructed, and the accuracy of head and neck squamous cell carcinoma detection and prognosis prediction in the prior art was solved. and safety issues, achieving high accuracy detection and prognosis prediction of head and neck squamous cell carcinoma, and are suitable for a variety of cancers.

CN119082300APending Publication Date: 2024-12-06SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411099733.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art lacks suitable methods for detection and prognosis prediction of head and neck squamous cell carcinoma. The traditional methods have radioactive radiation risks and detection errors, and the prognosis prediction of tumors with high heterogeneity is not accurate enough.

Method used

The expression levels of these markers were detected by PCR, in situ hybridization or high-throughput sequencing platforms to construct head and neck squamous cell carcinoma detection model and Prognostic model for detection of tissue and serum samples.

Benefits of technology

Accurate detection and prognosis prediction of head and neck squamous cell carcinoma is achieved, radioactive radiation is avoided, and is suitable for a variety of cancers. The detection results are stable and do not require multi-point sampling, which improves the accuracy and adaptability of the detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082300A_ABST
    Figure CN119082300A_ABST
Patent Text Reader

Abstract

The invention discloses a miRNA (micro Ribonucleic Acid) combined marker and application of the miRNA combined marker in preparation of a product for cancer detection and / or prediction and prognosis. The miRNA combined marker comprises miR-125b-5p, miR-411-5p and miR-99a-5p. Detection and prognosis prediction can be carried out on a patient by detecting the expression level of the miRNA combined marker in tumor tissue or serum of the patient suffering from the head and neck squamous cell carcinoma, and compared with a traditional detection method and a prognosis prediction method of the head and neck squamous cell carcinoma, radioactive radiation does not exist in detection of the expression level of the miRNA combined marker, and the detection result is accurate. The method has the advantages of simple operation, wide population adaptability, stable expression of the miRNA combined marker in tumor tissues or serum, no need of multi-point sampling during detection, and accurate detection result.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to a miRNA combination marker and its application in preparing cancer detection and / or prognosis prediction products. Background Art

[0002] Head and neck squamous cell carcinoma is a type of malignant tumor originating from the epithelial cells of the upper respiratory tract mucosa, such as the oral cavity, pharynx (nasopharynx, oropharynx, hypopharynx), and larynx, accounting for more than 90% of head and neck tumors. At present, there is no suitable method for detecting and predicting the prognosis of head and neck squamous cell carcinoma.

[0003] From the perspective of head and neck squamous cell carcinoma detection, the currently recommended detection methods are enhanced CT and puncture pathology. However, enhanced CT has a certain amount of radioactive radiation, and patients with renal insufficiency or contrast agent allergy cannot be examined. Although puncture pathology is the gold standard for diagnosing head and neck squamous cell carcinoma, due to the relatively scattered lesions of head and neck squamous cell carcinoma, multiple sites need to be sampled during pathological examination. Due to the limitation of the number of samples, the results of puncture pathology examination have a certain degree of error.

[0004] From the perspective of prognosis prediction for head and neck squamous cell carcinoma, the prognosis of cancer is usually related to the diagnosis and treatment timing of cancer. The earlier the patient is treated, the higher the prognosis survival rate. However, due to the large heterogeneity of head and neck squamous cell carcinoma tumors, even patients with different head and neck squamous cell carcinomas of the same clinical stage may have large differences in their prognosis after receiving the same surgical treatment.

[0005] Therefore, there is an urgent need to provide a detection and prognosis prediction method for head and neck squamous cell carcinoma with wide adaptability and accurate detection results. Summary of the invention

[0006] The purpose of the present invention is to solve the problem that there is currently no suitable method for detecting and predicting the prognosis of head and neck squamous cell carcinoma.

[0007] In order to achieve the above object, the present invention provides a miRNA combination marker, which includes: miR-125b-5p, miR-411-5p and miR-99a-5p.

[0008] Furthermore, the present invention also provides the use of a reagent for detecting the expression level of the above-mentioned miRNA combination marker in the preparation of a product for cancer detection and / or prognosis prediction, wherein the cancers include: head and neck squamous cell carcinoma, invasive breast cancer, bile duct carcinoma, renal chromophobe cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, hepatocellular carcinoma of the liver, thyroid cancer, and endometrial cancer.

[0009] Furthermore, the above product can detect the expression level of miRNA combination markers through PCR, in situ hybridization, or high-throughput sequencing platform, and the test sample can be a tissue sample and / or serum.

[0010] Furthermore, the present invention also provides a kit for detecting and / or predicting the prognosis of head and neck squamous cell carcinoma, wherein the kit comprises a reagent for detecting the expression level of the miRNA combination marker, and the reagent comprises a probe and / or a primer.

[0011] Furthermore, the sequences of the above primers are shown in SEQ ID NO.1-9.

[0012] The present invention also provides a head and neck squamous cell carcinoma tissue prognostic model, which is X=0.22406×Exp(miR-411-5p)-0.21409×Exp(miR-99a-5p)-0.00089×Exp(miR-125b-5p); if X>-1.0289, the patient has a high risk of prognosis, and if X≤-1.0289, the patient has a low risk of prognosis.

[0013] Furthermore, the present invention also provides a tissue head and neck squamous cell carcinoma detection model, the detection sample of the tissue head and neck squamous cell carcinoma detection model is tissue, and the tissue head and neck squamous cell carcinoma detection model is Y=19.381+0.481×Exp(miR-125b-5p)-1.414×Exp(miR-411-5p)-1.700×Exp(miR-99a-5p); if Y>2.2849, the detection subject has a higher risk of head and neck squamous cell carcinoma, and if Y≤2.2849, the detection subject has a lower risk of head and neck squamous cell carcinoma.

[0014] Furthermore, the present invention also provides a serum head and neck squamous cell carcinoma detection model, the detection sample of the serum head and neck squamous cell carcinoma detection model is serum, and the serum head and neck squamous cell carcinoma detection model is Z=0.064+20.664×Exp(miR-125b-5p)+18.143×Exp(miR-411-5p)-18.836×Exp(miR-99a-5p); if Z>0.0243, the detection subject has a higher risk of head and neck squamous cell carcinoma, and if Z≤0.0243, the detection subject has a lower risk of head and neck squamous cell carcinoma.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] The present invention provides a miRNA combination marker for head and neck squamous cell carcinoma detection and prognosis prediction, and a head and neck squamous cell carcinoma detection model and a prognosis model constructed based on the miRNA combination marker.

[0017] The present invention can detect and predict the prognosis of head and neck squamous cell carcinoma patients by detecting the expression level of miRNA combination markers in the tumor tissue or serum of the patient. Compared with the traditional head and neck squamous cell carcinoma detection method and prognosis prediction method, the present invention does not involve radioactive radiation in the detection of miRNA combination marker expression level, has wide population adaptability, and the expression of miRNA combination markers in tumor tissue or serum is stable, does not require multi-point sampling during detection, and the detection result is more accurate. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 This is a distribution diagram of differentially expressed miRNAs in the TCGA-HNSC dataset, GSE246050 dataset and clinical dataset (OSCC) of the present invention.

[0019] Figure 2 This is the expression heat map of the differentially expressed miRNAs of the present invention in head and neck squamous cell carcinoma samples and healthy samples.

[0020] Figure 3 The figure shows the differentially expressed numbers of the differentially expressed miRNAs of the present invention in head and neck squamous cell carcinoma samples and healthy samples.

[0021] Figure 4 This is a result diagram of analyzing differentially expressed miRNA using Lasso regression in the present invention;

[0022] A: LASSO regression parameter diagram;

[0023] B: LASSO coefficient distribution diagram.

[0024] Figure 5 This is a graph showing the results of analyzing differentially expressed miRNAs using univariate COX regression and Kaplan-Meier survival analysis in the present invention.

[0025] Figure 6 This is a distribution diagram of the key miRNA of the present invention in Lasso regression, univariate COX regression, and Kaplan-Meier survival analysis results.

[0026] Figure 7 The result graph of the receiver operating characteristic curve for key miRNAs in the present invention is shown.

[0027] Figure 8 This is a differential expression diagram of three head and neck squamous cell carcinoma-related miRNAs "miR-411-5p, miR-99a-5p, miR-125b-5p" in the TCGA-HNSC dataset tumor tissue and normal tissue;

[0028] A: Expression of miR-411-5p, miR-99a-5p, and miR-125b-5p in head and neck squamous cell carcinoma samples and normal control samples;

[0029] B: Expression trend of miR-411-5p, miR-99a-5p, and miR-125b-5p in head and neck squamous cell carcinoma samples and matched normal control samples.

[0030] Fig. 9 This is a graph showing the expression of three head and neck squamous cell carcinoma-related miRNAs "miR-411-5p, miR-99a-5p, miR-125b-5p" of the present invention in HACAT cells (human immortalized epidermal cells, representing normal cells), CAL27 cells (human tongue squamous cell carcinoma cells), HN4 cells (human laryngeal squamous cell carcinoma cells), HN6 cells (human tongue squamous cell carcinoma cells), OSCC25 cells (oral squamous cell carcinoma cells), and OSCC9 cells (oral squamous cell carcinoma cells).

[0031] Fig.10 This is a comparison diagram of the PCA model constructed based on 3 head and neck squamous cell carcinoma-related miRNAs and 96 differentially expressed miRNAs in the present invention;

[0032] A: PCA model constructed based on 96 head and neck squamous cell carcinoma-related miRNAs;

[0033] B: PCA model constructed based on three differentially expressed miRNAs.

[0034] Fig.11 This is a survival curve result diagram of the Training group drawn based on the head and neck squamous cell carcinoma tissue prognostic model formula of the present invention.

[0035] Fig.12 The risk score distribution diagram and survival status distribution diagram of the Training group drawn based on the head and neck squamous cell carcinoma tissue prognostic model formula of the present invention.

[0036] Fig.13 This is a graph of the survival curve results of the Testing group drawn based on the head and neck squamous cell carcinoma tissue prognostic model formula of the present invention.

[0037] Fig.14 A receiver operating characteristic curve of the Training group was drawn for the scoring of the head and neck squamous cell carcinoma detection model based on tissue in the present invention.

[0038] Fig.15 A receiver operating characteristic curve was drawn for the head and neck squamous cell carcinoma detection model scoring based on serum (GSE113956 database) of the present invention.

[0039] Fig.16The receiver operating characteristic curve was drawn for the invasive breast cancer tissue samples in the TCGA database in the present invention.

[0040] Fig.17 The receiver operating characteristic curve was drawn for the cholangiocarcinoma tissue samples in the TCGA database in the present invention.

[0041] Fig.18 A receiver operating characteristic curve was drawn for the renal chromophobe cell carcinoma tissue samples in the TCGA database in the present invention.

[0042] Fig.19 A receiver operating characteristic curve was drawn for the present invention based on renal clear cell carcinoma tissue samples in the TCGA database.

[0043] Fig. 20 A receiver operating characteristic curve was drawn for the renal papillary cell carcinoma tissue samples in the TCGA database in the present invention.

[0044] Fig.21 The receiver operating characteristic curve was drawn for the thyroid cancer tissue samples in the TCGA database in the present invention.

[0045] Fig. 22 A receiver operating characteristic curve was drawn for the liver hepatocellular carcinoma tissue samples in the TCGA database based on the present invention.

[0046] Fig.23 The receiver operating characteristic curve is drawn for the endometrial cancer tissue samples in the TCGA database in the present invention.

[0047] In the figure: "hsa-" before miRNA indicates miRNA derived from humans, such as "hsa-miR-411-5p" indicates "miR-411-5p" derived from humans. DETAILED DESCRIPTION

[0048] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and embodiments.

[0049] Terminology

[0050] miRNA: A non-coding RNA molecule consisting of approximately 19-25 nucleotides that can inhibit the translation of target mRNA and negatively regulate gene expression by complementary binding to target mRNA.

[0051] Pericancerous tissue: tissue about 2 cm away from the tumor lesion.

[0052] Based on the background technology, there is currently no suitable detection method and prognosis prediction method for head and neck squamous cell carcinoma. In order to solve this technical problem, the present invention provides a group of miRNA combination markers, including: miR-125b-5p, miR-411-5p and miR-99a-5p. And based on the miRNA combination marker, the present invention also provides a head and neck squamous cell carcinoma detection model and a head and neck squamous cell carcinoma prognosis model. When detecting and predicting the prognosis of head and neck squamous cell carcinoma patients, the present invention can detect and predict the prognosis of head and neck squamous cell carcinoma for the patient by detecting the expression level of the miRNA combination marker in the patient's tumor tissue or serum. Compared with the traditional detection method and prognosis prediction method for head and neck squamous cell carcinoma, the detection of the expression level of the miRNA combination marker in the present invention does not involve radioactive radiation, has a wide range of adaptability to the population, and the expression of the miRNA combination marker in the tumor tissue or serum is stable, and multi-point sampling is not required during detection, and the detection result is relatively accurate.

[0053] The following is a specific description with reference to embodiments.

[0054] Example 1 Screening of markers related to head and neck squamous cell carcinoma

[0055] Head and neck squamous cell carcinoma-related markers were screened using three independent data sets: TCGA-HNSC data set, GSE246050 data set, and clinical data set.

[0056] The TCGA-HNSC dataset was downloaded from the UCSC Xena data portal (https: / / xenabrowser.net / ) and The Cancer Genome Atlas Program database (TCGA, https: / / portal.gdc.cancer.gov / ).

[0057] The present invention collects all samples with head and neck squamous cell carcinoma expression profile data in the TCGA database, a total of 568 samples, including 524 tumor tissue samples and 44 normal control tissue samples of tumor patients.

[0058] The GSE246050 dataset (tissue samples, n=6, Tumor=3, Normal=3) was downloaded from Gene Expression Omnibus (GEO) (https: / / www.ncbi.nlm.nih.gov / gds / ).

[0059] Clinical dataset (OSCC): miRNA sequencing results extracted from tumor tissues and adjacent tissues of 10 patients with head and neck squamous cell carcinoma (tissue samples, n=20, Tumor=10, Normal=10).

[0060] The miRNA expression levels of each sample in the above three independent data sets were normalized and expressed as log2(RPM+1) values. Univariate analysis was used to identify miRNAs with significant differences in expression levels between head and neck squamous cell carcinoma samples and normal control samples in each data set. The screening criteria were |Log2FC|>0.585 (i.e., FC>1.5 or FC<0.667, the difference in miRNA expression levels between head and neck squamous cell carcinoma samples and normal control samples was greater than or less than 1.5 times) and P<0.05. The screened miRNAs were differentially expressed miRNAs.

[0061] like Figure 1 As shown in Figure 1, the differentially expressed miRNAs obtained from each data set were intersected, and finally 99 differentially expressed miRNAs were obtained. Then, the differential expression trends of the 99 differentially expressed miRNAs in the three data sets were analyzed, as shown in Figure 1. Figure 2 and Figure 3 As shown, the differential expression trends of the 96 miRNAs in the three data sets were consistent (compared with the normal control samples, 54 miRNAs were down-regulated in the three data sets, and 42 miRNAs were up-regulated in the three data sets).

[0062] Lasso regression and univariate COX regression combined with Kaplan-Meier survival analysis were performed on the 96 differentially expressed miRNAs, and then the results were intersected.

[0063] The Lasso regression method is as follows:

[0064] LASSO regression was performed using R language, and the 96 differentially expressed miRNAs were fitted with a generalized linear model. Variable screening and complexity adjustment were performed to obtain the LASSO regression parameter diagram ( Figure 4 A) and coefficient distribution diagram ( Figure 4 Figure B), select the lambda value with the smallest deviation (λmin, Figure 4 The number of variables corresponding to the left dashed line of Figure B (in Figure 4 The upper horizontal axis number in Figure B indicates that in this embodiment, the variable value is 13), and the variables whose coefficients are not 0 in this case are selected as key miRNAs, obtaining 13 key miRNAs.

[0065] The univariate COX regression and Kaplan-Meier survival analysis methods are as follows:

[0066] like Figure 5As shown, 96 differentially expressed miRNAs were analyzed using univariate COX regression and Kaplan-Meier survival analysis, and variables with P < 0.05 were taken as key miRNAs. The analysis results of the two were intersected to obtain 14 key miRNAs.

[0067] like Figure 6 As shown, the intersection of Lasso regression, univariate COX regression, and Kaplan-Meier survival analysis results showed that 9 key miRNAs existed simultaneously in the Lasso regression, univariate COX regression, and Kaplan-Meier survival analysis results.

[0068] Different combination models were constructed for 9 miRNAs, and the receiver operating characteristic curve was drawn based on the Training group. The area under the curve was calculated to determine its potential diagnostic value in detecting patients with head and neck squamous cell carcinoma. Finally, miRNAs with high AUC values, "miR-411-5p, miR-99a-5p, and miR-125b-5p", were selected as miRNA markers related to head and neck squamous cell carcinoma.

[0069] Example 2 Validation of miRNA markers related to head and neck squamous cell carcinoma

[0070] The TCGA-HNSC dataset was used as a validation dataset to verify the above three head and neck squamous cell carcinoma-related miRNA markers. Figure 8 As shown, compared with normal control samples, "miR-411-5p, miR-99a-5p, miR-125b-5p" were downregulated in tumor tissues with significant differences. Figure 8 Figure A shows the expression of miR-411-5p, miR-99a-5p, and miR-125b-5p in head and neck squamous cell carcinoma samples and normal control samples in the TCGA-HNSC dataset. Figure 8 B is the expression change trend chart of miR-411-5p, miR-99a-5p, and miR-125b-5p in head and neck squamous cell carcinoma samples and paired (from the same patient) normal control samples in the TCGA-HNSC dataset.

[0071] Furthermore, the present application performed RT-qPCR verification with CAL27 cells (human tongue squamous cell carcinoma cells), HN4 cells (human laryngeal squamous cell carcinoma cells), HN6 cells (human tongue squamous cell carcinoma cells), OSCC25 cells (oral squamous cell carcinoma cells), and OSCC9 cells (oral squamous cell carcinoma cells) to check whether the three head and neck squamous cell carcinoma-related miRNA markers were also downregulated in head and neck squamous cell carcinoma cell lines compared with normal cells. Fig. 9As shown, compared with HACAT cells (human immortalized epidermal cells, representing normal cells), the three head and neck squamous cell carcinoma-related miRNA markers were all downregulated in the above head and neck squamous cell carcinoma cell lines, which was consistent with their verification results in the TCGA-HNSC dataset.

[0072] The primers used for RT-qPCR are as follows:

[0073] miR-411-5p stem-loop primer (SEQ ID No. 1): GTCGTATCCAGTGCAGGG TCCGAGGTATTCGCACTGGATACGACCGTACG

[0074] miR-411-5p forward primer (SEQ ID No. 2): AAGCGCCTTAGTAGAC CGTAT

[0075] miR-411-5p reverse primer (SEQ ID No. 3): GTCGTATCCAGTGCAG GGT

[0076] miR-99a-5p stem-loop primer (SEQ ID No. 4): GTCGTATCCAGTGCAG GGTCCGAGGTATTCGCACTGGATACGACCACAAG

[0077] miR-99a-5p forward primer (SEQ ID No. 5): AACACGTGAACCCGTA GATCC

[0078] miR-99a-5p reverse primer (SEQ ID No. 6): GTCGTATCCAGTGCAG GGT

[0079] miR-125b-5p stem-loop primer (SEQ ID No. 7): GTCGTATCCAGTGCAG GGTCCGAGGTATTCGCACTGGATACGACTCACAA

[0080] miR-125b-5p forward primer (SEQ ID No. 8): AACAGTGTCCCTGAGA CCCTA

[0081] miR-125b-5p reverse primer (SEQ ID No. 9): GTCGTATCCAGTGCAG GGT.

[0082] Example 3 Establishment of a prognostic model for head and neck squamous cell carcinoma tissue

[0083] Based on the TCGA-HNSC database, the TCGA-HNSC database was randomly divided into two groups: Training group and Testing group. The Training group included 260 head and neck squamous cell carcinoma samples, and the Testing group included 261 head and neck squamous cell carcinoma samples.

[0084] Based on the training group data, the head and neck squamous cell carcinoma tissue prognostic model was constructed according to the tissue expression levels of three head and neck squamous cell carcinoma-related miRNAs "miR-125b-5p, miR-411-5p and miR-99a-5p" in head and neck squamous cell carcinoma patients: combined with the survival status and survival time of each sample in the TCGA-HNSC database, a multifactor stepwise COX regression analysis was performed to obtain the coefficients of the three head and neck squamous cell carcinoma-related miRNAs (as shown in Table 1), and the head and neck squamous cell carcinoma tissue prognostic model was established. The formula for the head and neck squamous cell carcinoma tissue prognostic model for each patient is as follows:

[0085] X=0.22406×Exp(miR-411-5p)-0.21409×Exp(miR-99a-5p)-0.00089×Exp(miR-125b-5p); wherein "Exp(miRNA)" in the formula represents the expression level of the miRNA, expressed as the log2(RPM+1) value, such as Exp(miR-411-5p) represents the expression level of miR-411-5p, expressed as the log2(RPM+1) value of miR-411-5p.

[0086] Table 1 Coefficients of three head and neck squamous cell carcinoma-related miRNAs in multivariate stepwise COX regression analysis

[0087] id Coefficient (coef) Hazard ratio (HR) HR (95% Cl) P value miR-411-5p 0.224066 1.2511537 1.05932758-1.47771625 0.008323 miR-99a-5p -0.21409 0.80727323 0.70581745-0.92331249 0.001782 miR-125b-5p -0.00089 1.19448227 0.87251559-1.63525777 0.267447

[0088] According to the median of the prognostic model score of head and neck squamous cell carcinoma tissue (in this embodiment, the median is -1.0289), the samples were divided into a high-risk group and a low-risk group, and a survival curve was drawn based on the survival-related information. Fig.11 As shown in the data, the overall survival rate of the high-risk group was significantly lower than that of the low-risk group (p<0.05).

[0089] Furthermore, the risk score distribution diagram and survival status distribution diagram of the Training group samples were drawn. Fig.12 As shown, as the risk score increases, the mortality rate of the high-risk group is higher than that of the low-risk group. If the risk score is greater than -1.0289, the patient has a high prognostic risk, and the mortality rate of the high-risk prognostic group is equal to 50.000%; if the risk score is ≤-1.0289, the patient has a low prognostic risk, and the mortality rate of the low-risk prognostic group is equal to 34.375%.

[0090] Next, the prognostic model formula for head and neck squamous cell carcinoma tissues was verified using the Testing group. The risk scores of each sample in the Testing group were calculated according to the prognostic model formula. Patients with a risk score of >-1.0289 were in the high-risk prognosis group, and patients with a risk score of ≤-1.0289 were in the low-risk prognosis group. Combined with survival-related information, a survival curve was drawn. The results are shown in Figure 2. Fig.13 As shown in the data, the overall survival rate of the high-risk group was indeed significantly lower than that of the low-risk group (p<0.05).

[0091] On this basis, based on the TCGA-HNSC database, a PCA model was constructed according to the tissue expression levels of three HNSCC-related miRNAs "miR-125b-5p, miR-411-5p and miR-99a-5p" in HNSCC patients and compared with the PCA model constructed based on 96 differentially expressed miRNAs.

[0092] The results are as follows Fig.10 As shown, Fig.10 Figure A shows the PCA model constructed based on 96 differentially expressed miRNAs. Fig.10 Figure B is a PCA model constructed based on three head and neck squamous cell carcinoma-related miRNAs. Compared with the two, the PCA model constructed based on three head and neck squamous cell carcinoma-related miRNAs can significantly separate patients with high and low prognosis risks of head and neck squamous cell carcinoma.

[0093] The above results indicate that the head and neck squamous cell carcinoma tissue prognostic model provided in this embodiment can effectively predict the low survival rate and prognosis of head and neck squamous cell carcinoma patients.

[0094] Example 4 Establishment of a head and neck squamous cell carcinoma detection model

[0095] (1) Establishment of a tissue-based head and neck squamous cell carcinoma detection model

[0096] Based on the TCGA-HNSC database, the TCGA-HNSC database was randomly divided into two groups: Training group and Testing group. The Training group included 260 head and neck squamous cell carcinoma samples and 22 normal control samples, and the Testing group included 261 head and neck squamous cell carcinoma samples and 22 normal control samples.

[0097] Based on the data of the Training group, a tissue head and neck squamous cell carcinoma detection model was constructed according to the tissue expression levels of three head and neck squamous cell carcinoma-related miRNAs "miR-125b-5p, miR-411-5p and miR-99a-5p" in patients with head and neck squamous cell carcinoma: the expression levels of the three miRNAs were used as covariates, and whether the sample was a head and neck squamous cell carcinoma was used as the dependent variable. Binary logistic regression analysis was performed using IBM SPSS Statistics 26 software to obtain the coefficients of the three head and neck squamous cell carcinoma-related miRNAs (as shown in Table 2), and a tissue head and neck squamous cell carcinoma detection model was established. The formula for the tissue head and neck squamous cell carcinoma detection model for each patient is as follows:

[0098] Y=19.381+0.481×Exp(miR-125b-5p)-1.414×Exp(miR-411-5p)-1.700×Exp(miR-99a-5p); wherein “Exp(miRNA)” in the formula represents the expression level of the miRNA, expressed as the log2(RPM+1) value, such as Exp(miR-411-5p) represents the expression level of miR-411-5p, expressed as the log2(RPM+1) value of miR-411-5p.

[0099] Table 2 Coefficients of three head and neck squamous cell carcinoma-related miRNAs in tissues analyzed by binary logistic regression

[0100]

[0101] The receiver operating characteristic curve was drawn based on the score of the head and neck squamous cell carcinoma detection model. The results are as follows: Fig.14 As shown, the tissue head and neck squamous cell carcinoma detection model provided in this embodiment showed an AUC of 0.955 (p<0.05) in the head and neck squamous cell carcinoma tissue Training group samples, with a sensitivity of 91.20% and a specificity of 90.90%. Compared with a single miRNA, it has a higher AUC value and a higher sensitivity. When the model score is >2.2849, it has detection significance, that is, when the model score is >2.2849, the detection object has a higher risk of head and neck squamous cell carcinoma, and when the model score is ≤2.2849, the detection object has a lower risk of head and neck squamous cell carcinoma.

[0102] Next, based on the tissue head and neck squamous cell carcinoma detection model formula obtained in the Training group, the Testing group was used for verification. The model score of each sample in the Testing group was calculated according to the detection model formula. Patients with model scores > 2.2849 were patients with head and neck squamous cell carcinoma, and patients with risk scores ≤ 2.2849 were normal controls. According to the clinical information provided by the TCGA-HNSC database of the Testing group, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the detection model were calculated. The results are shown in Table 3. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the prediction model in the Testing group were 90.04%, 100.00%, 100.00%, 45.83% and 90.81%.

[0103] Table 3 Detection and verification results of the testing group of the head and neck squamous cell carcinoma detection model

[0104]

[0105] (2) Establishment of a serum head and neck squamous cell carcinoma detection model

[0106] Based on the GSE113956 database, a serum head and neck squamous cell carcinoma detection model was constructed according to the serum expression levels of three head and neck squamous cell carcinoma-related miRNAs "miR-125b-5p, miR-411-5p and miR-99a-5p" in patients with head and neck squamous cell carcinoma: the expression levels of the three miRNAs were used as covariates, and whether the sample was head and neck squamous cell carcinoma was used as the dependent variable. IBM SPSS Statistics 26 software was used for binary logistic regression analysis, and the coefficients of the three head and neck squamous cell carcinoma-related miRNAs were obtained (as shown in Table 4), and a serum head and neck squamous cell carcinoma detection model was established. The formula of the serum head and neck squamous cell carcinoma detection model for each patient is as follows:

[0107] Z=0.064+20.664×Exp(miR-125b-5p)+18.143×Exp(miR-411-5p)-18.836×Exp(miR-99a-5p); wherein “Exp(miRNA)” in the formula represents the expression level of the miRNA, expressed as the log2(RPM+1) value, such as Exp(miR-411-5p) represents the expression level of miR-411-5p, expressed as the log2(RPM+1) value of miR-411-5p.

[0108] Table 4 Coefficients of three head and neck squamous cell carcinoma-related miRNAs in serum by binary logistic regression analysis

[0109]

[0110] The receiver operating characteristic curve was drawn based on the serum head and neck squamous cell carcinoma detection model score. The results are as follows Fig.15 As shown, the serum head and neck squamous cell carcinoma detection model provided in this embodiment shows an AUC of 0.944 (p<0.05) in serum samples of head and neck squamous cell carcinoma patients, with a sensitivity of 88.00% and a specificity of 93.33%. Compared with a single miRNA, it has a higher AUC value and higher sensitivity and specificity. When the model score is >0.0243, it has diagnostic significance, that is, when Z>0.0243, the test subject has a higher risk of head and neck squamous cell carcinoma, and when Z≤0.0243, the test subject has a lower risk of head and neck squamous cell carcinoma.

[0111] Example 5 Role of three head and neck squamous cell carcinoma-related miRNAs in other cancers

[0112] Based on the invasive breast cancer tissue samples in the TCGA database, the receiver operating characteristic curve was drawn. Fig.16 As shown, the combination of “miR-125b-5p, miR-411-5p and miR-99a-5p” expression levels showed an AUC of 0.978 (p<0.05) with a sensitivity of 95.60% and a specificity of 94.10% in invasive breast cancer (BRCA) tissue samples.

[0113] Based on the cholangiocarcinoma tissue samples in the TCGA database, the receiver operating characteristic curve was drawn. Fig.17 As shown, the combination of “miR-125b-5p, miR-411-5p and miR-99a-5p” expression levels showed an AUC of 0.915 (p<0.05) with a sensitivity of 85.00% and a specificity of 90.00% in cholangiocarcinoma (CHOL) tissue samples.

[0114] Based on the renal chromophobe cell carcinoma tissue samples in the TCGA database, the receiver operating characteristic curve was drawn. Fig.18 As shown, the combination of "miR-125b-5p, miR-411-5p and miR-99a-5p" expression levels showed an AUC of 0.947 (p<0.05) with a sensitivity of 91.70% and a specificity of 90.80% in renal chromophobe cell carcinoma (KICH) tissue samples.

[0115] Based on the renal clear cell carcinoma tissue samples in the TCGA database, the receiver operating characteristic curve was drawn. Fig.19 As shown, the combination of “miR-125b-5p, miR-411-5p and miR-99a-5p” expression levels showed an AUC of 0.931 (p<0.05) with a sensitivity of 97.10% and a specificity of 78.40% in renal clear cell carcinoma (KIRC) tissue samples.

[0116] Based on the renal papillary cell carcinoma tissue samples in the TCGA database, the receiver operating characteristic curve was drawn. Fig. 20 As shown, the combination of “miR-125b-5p, miR-411-5p and miR-99a-5p” expression levels showed an AUC of 0.936 (p<0.05) with a sensitivity of 91.20% and a specificity of 87.80% in renal papillary cell carcinoma (KIRP) tissue samples.

[0117] Based on the liver hepatocellular carcinoma tissue samples in the TCGA database, the receiver operating characteristic curve was drawn. Fig.21 As shown, the combination of “miR-125b-5p, miR-411-5p and miR-99a-5p” expression levels showed an AUC of 0.979 (p<0.05) with a sensitivity of 98.00% and a specificity of 91.00% in liver hepatocellular carcinoma (LIHC) tissue samples.

[0118] Based on the thyroid cancer tissue samples in the TCGA database, the receiver operating characteristic curve was drawn. Fig. 22 As shown, the combination of “miR-125b-5p, miR-411-5p and miR-99a-5p” expression levels showed an AUC of 0.924 (p<0.05) in thyroid cancer (THCA) tissue samples, with a sensitivity of 91.50% and a specificity of 82.20%.

[0119] Based on the endometrial cancer tissue samples in the TCGA database, the receiver operating characteristic curve was drawn. Fig.23 As shown, the combination of “miR-125b-5p, miR-411-5p and miR-99a-5p” expression levels showed an AUC of 0.940 (p<0.05) with a sensitivity of 99.50% and a specificity of 83.20% in endometrial cancer (UCEC) tissue samples.

[0120] The above results show that compared with a single miRNA, the combination of "miR-125b-5p, miR-411-5p and miR-99a-5p" has a higher AUC value in the detection of invasive breast cancer, bile duct cancer, renal chromophobe cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, hepatocellular carcinoma, thyroid cancer, and endometrial cancer, and has a good tumor screening effect on patients with the above cancers.

[0121] In summary, the present invention provides a miRNA combination marker for head and neck squamous cell carcinoma detection and prognosis prediction, as well as a head and neck squamous cell carcinoma detection model and a prognosis model constructed based on the miRNA combination marker.

[0122] The present invention can detect and predict the prognosis of head and neck squamous cell carcinoma patients by detecting the expression level of miRNA combination markers in the tumor tissue or serum of the patient. Compared with the traditional head and neck squamous cell carcinoma detection method and prognosis prediction method, the present invention does not involve radioactive radiation in the detection of miRNA combination marker expression level, has wide population adaptability, and the expression of miRNA combination markers in tumor tissue or serum is stable, does not require multi-point sampling during detection, and the detection result is more accurate.

[0123] Although the content of the present invention has been described in detail through the above preferred embodiments, it should be appreciated that the above description should not be considered as a limitation of the present invention. After reading the above content, it will be apparent to those skilled in the art that various modifications and substitutions of the present invention will occur. Therefore, the protection scope of the present invention should be limited by the appended claims.

Claims

1. A miRNA combination marker, characterized in that: The miRNA combination markers include: miR-125b-5p, miR-411-5p and miR-99a-5p.

2. Use of a reagent for detecting the expression level of the miRNA combination marker according to claim 1 in the preparation of a product for cancer detection and / or prognosis prediction, characterized in that: The cancers include: head and neck squamous cell carcinoma, invasive breast cancer, bile duct cancer, renal chromophobe cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, hepatocellular carcinoma, thyroid cancer, and endometrial cancer.

3. The use according to claim 2, characterized in that: The product detects the expression level of miRNA combination markers through PCR, in situ hybridization, or high-throughput sequencing platform.

4. The use according to claim 2, characterized in that: The test samples of the product are tissue samples and / or serum.

5. A kit for detecting and / or predicting prognosis of head and neck squamous cell carcinoma, characterized in that: The kit comprises a reagent for detecting the expression level of the miRNA combination marker according to claim 1, wherein the reagent comprises a probe and / or a primer.

6. The kit according to claim 5, characterized in that The sequences of the primers are shown in SEQ ID NO.1-9.

7. A head and neck squamous cell carcinoma tissue prognosis model, characterized in that: The prognostic model is X=0.22406×Exp(miR-411-5p)-0.21409×Exp(miR-99a-5p)-0.00089×Exp(miR-125b-5p); if X>-1.0289, the patient has a high risk of prognosis, and if X≤-1.0289, the patient has a low risk of prognosis.

8. A tissue head and neck squamous cell carcinoma detection model, characterized in that: The detection sample of the tissue head and neck squamous cell carcinoma detection model is tissue, and the tissue head and neck squamous cell carcinoma detection model is Y=19.381+0.481×Exp(miR-125b-5p)-1.414×Exp(miR-411-5p)-1.700×Exp(miR-99a-5p); if Y>2.2849, the detection subject has a higher risk of head and neck squamous cell carcinoma, and if Y≤2.2849, the detection subject has a lower risk of head and neck squamous cell carcinoma.

9. A serum head and neck squamous cell carcinoma detection model, characterized in that: The detection sample of the serum head and neck squamous cell carcinoma detection model is serum, and the serum head and neck squamous cell carcinoma detection model is Z=0.064+20.664×Exp(miR-125b-5p)+18.143×Exp(miR-411-5p)-18.836×Exp(miR-99a-5p); if Z>0.0243, the detection subject has a higher risk of head and neck squamous cell carcinoma, and if Z≤0.0243, the detection subject has a lower risk of head and neck squamous cell carcinoma.